Jan 28 (Reuters) - Lumibird SA LBIRD.PA :
* REPORTED ON MONDAY 2019 FULL-YEAR REVENUES AND REVISION OF
THE
2021 REVENUE TARGET
* Q4 REVENUE EUR 33.6 MLN VS EUR 35.2 MLN YEAR AGO
* TREND FOR ORGANIC GROWTH IS CONTINUING IN 2020 AND IS
EXPECTED
TO BE FURTHER STRENGTHENED WITH ELLEX’S ACTIVITIES FOR MEDICAL
BRANCH FOR AROUND EUR 40 MLN PRO FORMA
* TURNOVER TARGET OF EUR 150 MLN PER ORGANIC GROWTH IN 2021
IS
POSTPONED TO 2022
* MAINTAINS TARGET OF 20% EBITDA MARGIN FOR 2021
Source text for Eikon: ID:nBw9XttWwa
Further company coverage: LBIRD.PA
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))